Major GI events among elderly chronic users of COX-2s and non-selective NSAIDs, with/without aspirin

被引：0
|
作者：
Wang, J
Mullins, CD
Naradzay, JF
Howard, K
机构：
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[2] Pfizer, New York, NY USA
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64440-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A44 / A44
页数：1
相关论文
共 50 条
  • [41] Evaluating cardiovascular and gastrointestinal risks and benefits of COX-2 selective inhibitors and non-selective nsaids in osteoarthritis patients using a decision analytic model
    Mittmann, N.
    Risebrough, N.
    Choy, E.
    Knowles, S.
    Chen, C.
    Lising, A.
    Almeida, T.
    Koncz, T.
    Niculescu, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 504 - 504
  • [42] Co-Prescription of Gastroprotective Agents in Patients Taking Non-Selective NSAIDs or COX-2 Selective Inhibitors: A Hospital Based Retrospective Study
    Thobari, Jarir A. T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 415 - 415
  • [43] Effect of non-selective and selective cyclooxygenase (COX)-2 inhibitors and nitric oxide (NO)-releasing aspirin on esophageal damage in the rat model of reflux esophagitis
    Pawlik, Michal
    Brzozowski, Tomasz
    Konturek, Peter C.
    Sliwowski, Zbigniew
    Mazurkiewicz-Janik, Magdalena
    Kwiecien, Slawomir
    Drozdowicz, Danuta
    Konturek, Stanislaw J.
    Pawlik, Wieslaw W.
    GASTROENTEROLOGY, 2008, 134 (04) : A589 - A589
  • [44] Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand, Vibeke
    LANCET, 2007, 370 (9605): : 2138 - 2151
  • [45] Pharmacoeconomics of COX-2-selective inhibitors versus non-selective NSAIDs and concomitant coumarin use: Economic evaluation linked to a case-control study
    Postma, MJ
    Knijff-Dutmer, EA
    van der Palen, J
    van de Laar, MA
    Brouwers, JR
    VALUE IN HEALTH, 2003, 6 (06) : 726 - 726
  • [46] Both selective cox-2 inhibitors and non-selective nsaids increase the risk of acute myocardial infarction in patients with arthritis: Selectivity is with the patient, not the drug class
    Singh, G
    Mithal, A
    Triadafilopoulos, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 85 - +
  • [47] COX-2 and Non-Selective NSAID Use in Those at Increased Risk of NSAID-Related Adverse Events
    Ilomaki, Jenni
    Gadzhanova, Svetla
    Roughead, Elizabeth E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 70 - 70
  • [48] Selective cox-2 inhibitors rofecoxib and etoricoxib decrease serious lower gi clinical events as compared to nonselective NSAIDs: A meta-analysis
    Laine, L
    Reicin, AS
    Yu, Q
    Fearen, I
    Bolognese, JA
    Maller, ES
    OSTEOARTHRITIS AND CARTILAGE, 2004, 12 : S132 - S132
  • [49] The risk of non-selective NSAIDs and selective cyclooxygenase-2 inhibitors is not modified by use of evidence-based pharmacotherapy in chronic heart failure
    Gislason, Gunnar H.
    Rasmussen, Jeppe N.
    Abildstrom, Steen Z.
    Rasmussen, Soren
    Schramm, Tina K.
    Folke, Fredrik
    Hansen, Morten L.
    Kober, Lars
    Madsen, Mette
    Torp-Pedersen, Christian
    CIRCULATION, 2007, 116 (16) : 736 - 736
  • [50] COX-2 Inhibitor and Non-Selective NSAID Use in Those at Increased Risk of NSAID-Related Adverse Events
    Gadzhanova, Svetla
    Ilomaeki, Jenni
    Roughead, Elizabeth E.
    DRUGS & AGING, 2013, 30 (01) : 23 - 30
12345